Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactose Nigelle 5
- Development stage
- Unknown
- Lead developer
- Fractal Tun
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Lactose Nigelle 5 (also known as Nig5) is a fractalized formulation of Nigella sativa (black seed) developed by the Tunisian company Fractal Tun. It is currently being investigated in clinical trials, supervised by Hôpital Universitaire Sahloul, for its potential in preventing influenza-like illnesses, specifically COVID-19. The product is administered sublingually as a capsule once daily for 21 days. Nigella sativa is recognized for its immunomodulatory and anti-inflammatory properties, which are thought to be mediated by its active constituent, thymoquinone, although the precise molecular targets for this specific formulation are not explicitly defined in the trial context.
- Brand names
- Lactose Nigelle 5
- Other names
- Nigella SativaNigelle 5Nigelle5Nigelle-5
Beyond the preview
Go deeper on Lactose Nigelle 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactose Nigelle 5.